Intellia Therapeutics, Inc. (NTLA) Insider Trading

Over the last 3 months, NTLA insiders made 0 open-market buys and 3 sales, a net sale of -$220K (SEC Form 4). Over the last 6 months, 237 institutions increased and 160 reduced their position (13F).

Insider Activity

Sentiment
0/100
Buys (3m)
0
Sells (3m)
3
Net (3m)
-$219.8K
Insider trades by month Buys Sells
Jul
Aug
Oct
Dec
Jan
Jul
Context3-month price -19.5%Institutions accumulating (13F)
DateInsiderTypeSharesPrice
Jul 24, 2026Dulac Edward J IIIofficer: EVP, Chief Financial OfficerSell8,111$11.25
Jul 6, 2026Dulac Edward J IIIofficer: EVP, Chief Financial OfficerSell4,677$18.00
Jul 6, 2026Dube Michael Pofficer: VP, Chief Accounting OfficerSell2,641$16.78
Jun 10, 2026CHASE WILLIAM JdirectorGrant13,300$12.89
Jun 10, 2026Cohen Fred EdirectorGrant9,200—
Jun 10, 2026Keresty GeorgiadirectorGrant13,300$12.89
Jun 10, 2026CHASE WILLIAM JdirectorGrant9,200—
Jun 10, 2026Goff BriandirectorGrant13,300$12.89
Jun 10, 2026Cohen Fred EdirectorGrant13,300$12.89
Jun 10, 2026GOODMAN JESSEdirectorGrant13,300$12.89
Jun 10, 2026GOODMAN JESSEdirectorGrant9,200—
Jun 10, 2026Keresty GeorgiadirectorGrant9,200—
Jun 10, 2026Verwiel FrankdirectorGrant13,300$12.89
Jun 10, 2026Verwiel FrankdirectorGrant9,200—
Jun 10, 2026Bhanji MunadirectorGrant13,300$12.89
Jun 10, 2026Goff BriandirectorGrant9,200—
Jun 10, 2026Bhanji MunadirectorGrant9,200—
Jan 7, 2026Dulac Edward J IIIofficer: EVP, Chief Financial OfficerSell6,379$9.21
Jan 7, 2026BASTA JAMESofficer: EVP, General CounselSell10,397$9.21
Jan 7, 2026Clark Elianaofficer: EVP, Chief Technical OfficerSell9,515$9.21
Jan 7, 2026LEONARD JOHN Mdirector, officer: President and CEOSell34,146$9.21
Jan 7, 2026Lebwohl Davidofficer: EVP, Chief Medical OfficerSell11,903$9.21
Jan 7, 2026Cohen Fred EdirectorBuy150,000$9.35
Jan 7, 2026Schultes Birgit Cofficer: EVP, Chief Scientific OfficerSell8,508$9.21
Jan 7, 2026Dube Michael Pofficer: VP, Chief Accounting OfficerSell2,989$9.21
Dec 12, 2025LEONARD JOHN Mdirector, officer: President and CEOSell32,832$9.47
Dec 12, 2025LEONARD JOHN Mdirector, officer: President and CEOOption49,959$6.83
Dec 12, 2025LEONARD JOHN Mdirector, officer: President and CEOSell5,355$9.59
Dec 12, 2025LEONARD JOHN Mdirector, officer: President and CEOOption8,557$6.83
Dec 12, 2025LEONARD JOHN Mdirector, officer: President and CEOSell49,959$9.49

Source: NTLA SEC Form 4 filings, latest Jul 24, 2026. For informational purposes only — not investment advice.

Institutional activity (13F)

How institutions changed their NTLA positions over the last 6 months (SEC Form 13F).

Increased
237
New positions
124
Reduced
160
Sold out
90
Largest moves
InstitutionActionSharesFiled
ARK INVESTMENT MANAGEMENT LLCIncreased14.5MMay 12, 2026
ARK INVESTMENT MANAGEMENT LLCIncreased14.2MFeb 11, 2026
VANGUARD GROUP INCIncreased13.0MJan 29, 2026
BLACKROCK, INC.Increased12.2MMay 13, 2026
BLACKROCK, INC.Increased10.3MFeb 12, 2026
STATE STREET CORPIncreased6.9MMay 15, 2026
STATE STREET CORPIncreased6.4MFeb 13, 2026
VANGUARD PORTFOLIO MANAGEMENT LLCNew Position6.2MMay 8, 2026
D. E. SHAW & CO., INC.Increased5.7MMay 15, 2026
D. E. SHAW & CO., INC.Increased5.3MFeb 17, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position5.1MMay 15, 2026
TWO SIGMA INVESTMENTS, LPIncreased4.7MMay 15, 2026
REGENERON PHARMACEUTICALS, INC.Unchanged3.7MFeb 6, 2026
REGENERON PHARMACEUTICALS, INC.Unchanged3.7MMay 8, 2026
UBS GROUP AGIncreased3.3MMay 5, 2026

Source: SEC Form 13F filings. For informational purposes only — not investment advice.

← Back to NTLA overview (price, financials, earnings)